Fresenius Medical (FMS) is a “Dependable Top-Line Grower”, Says Fiduciary Management
Fiduciary Management Inc., an investment management firm, published its “International Equity” first quarter 2021 investor letter – a copy of which can be downloaded here. A return of 7.2% (currency hedged) was reported by the FMI International portfolios for the Q1 of 2021, compared to its MSCI EAFE benchmark that delivered a 7.59% return in local currency (LOC) and 3.48% in U.S. Dollars (USD) over the same period. You can view the fund’s top 5 holdings to have a peek at their top bets for 2021.
Fiduciary Management, in their Q1 2021 investor letter, mentioned Fresenius Medical Care AG & Co. KGaA (NYSE: FMS) and shared their insights on the company. Fresenius Medical Care AG & Co. KGaA Limited is a Bad Homburg, Germany-based kidney dialysis centers company that currently has a $22.2 billion market capitalization. Since the beginning of the year, FMS delivered a -8.76% return, while i
Medical Device Market Size to Grow at a CAGR of 5 7% During the Forecast Period 2020-2025 briefingwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from briefingwire.com Daily Mail and Mail on Sunday newspapers.
Insurers are partnering to offload the costs of kidney failure patients
Insurers are partnering to offload the costs of kidney failure patients
Print
Blue Cross and Blue Shield of Minnesota inked a new value-based care plan with a DaVita Kidney Care affiliate on Monday, in a move to provide more cost-effective treatment to its new cohort of Medicare Advantage members.
The partnership represents the latest example of an insurer rushing to offload or at least, better manage the risk of patients suffering from permanent kidney failure, who are now eligible to enroll in Advantage plans for the first time this year.
Healthcare Leader Jason Thomas Named President and COO of Central Ohio Urology Group yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
ResearchAndMarkets.com s offering.
The global end stage renal disease market is estimated to be USD 73.1 billion in 2020 and is expected to reach USD 137.08 billion by 2025, growing at a CAGR of 13.4 %.
Market Dynamics
The increasing number of patients suffering from kidney failure and the introduction of technologically advanced products, such as low maintenance dialysis equipment and artificial kidney, are the major factors expected to drive the end stage renal disease (ESRD) market. The ongoing Covid-19 pandemic has resulted in an increased demand for home dialysis across the globe.
Market Segmentation
The Global End Stage Renal Disease Market is segmented further based on Disease Type, Treatment Type, End User, and Geography.